




RealRate

PHARMACEUTICAL 2020

Astria Therapeutics Inc. Rank 114 of 358





PHARMACEUTICAL 2020

Astria Therapeutics Inc.
Rank 114 of 358



The relative strengths and weaknesses of Astria Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Astria Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 96% points. The greatest weakness of Astria Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 147%, being 111% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	38,958
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,032
Liabilities, Non-Current	1,028
Other Assets	2,822
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	795
Other Revenues	0
Property and Equipment	0
Research and Development	18,317
Selling, General and Administrative Expense	8,771

Output Variable	Value in 1000 USD
Assets	41,780
Liabilities	6,060
Expenses	27,088
Revenues	0
Stockholders Equity	35,720
Net Income	-26,293
Comprehensive Net Income	-26,293
Economic Capital Ratio	147%